Cystic Fibrosis and Periodontal Diseases

Not Applicable

Recruiting

• Conditions: Periodontitis; Gingivitis; Cystic Fibrosis
• Interventions: Other: Periodontal examination

• Registration Number: NCT06133335
• Lead Sponsor: CHU de Reims

Brief Summary

The number of CF adults is increasing year after year (61.7% in 2021) confirming that patients are living longer. These data do not leave aside the desire to see CF patients "age well" considering of all the comorbidities linked to aging.

Among these comorbidities, the oral repercussions of cystic fibrosis and its treatments remain to this day little investigated. We know, however, that oral health, and periodontal health, is closely linked to general health. Indeed, the oral cavity presents one of the richest microbiota in the body, made up of bacteria, viruses, yeasts and archae organized into a biofilm at the interface of periodontal tissues. Periodontal diseases are partly linked to an imbalance in and loss of diversity within the commensal periodontal flora, aggravated by risk factors such as diabetes, which affects many CF adults. Early detection and treatment of periodontal diseases are therefore of primary interest in patients at increased risk of respiratory infections such as CF patients. This transversal research project aims to study the oral repercussions, notably periodontal disease prevalence in cystic fibrosis (CF) adult patients.

Thus, this program will allow, on the one hand, the acquisition of clinical and biological data on periodontal and/or dental pathologies from which adult CF patients may suffer. These data will be accessible through an oral and periodontal clinical examination that will allow the identification of diagnostic clues. The quality of life related to oral health will also be investigated using a self-administered questionnaire. Clinical and biological data commonly recorded in the context of the medical follow-up of CF patients (ventilatory capacity, glycemic status, cytobacteriological examination of sputum, etc.) will also be taken into account in order to study any correlations with periodontal status.

On the other hand, on a more fundamental level, this work aims to investigate the impact of CFTR protein dysfunction on the local immunity of the oral cavity and more particularly on the expression of antimicrobial peptides at the level of the periodontium.

Thus this project is articulated around a strong axis which is "aging well" for adult CF patients thanks to the improvement of knowledge and ultimately the prevention of comorbidities linked to aging in CF adult patients and particularly those related to oral health.

Detailed Description

The main objective of this study is to determine the prevalence of periodontal disease in adult CF subjects followed at CRCM of the CHU of Reims. Periodontal diseases (periodontitis and gingivitis) will be diagnosed according to the international classification of periodontal diseases (Chicago 2017). Periodontal examination will be performed with periodontal probe PCP UNC15. The diagnosis of periodontal disease is defined from the decision algorithm including measurement of interdental attachment loss (CAL), measurement of gingival recession (REC) and depth of vestibular or lingual pocket (PPD) (Tonetti and Sanz 2019).The clinical indices noted will therefore include: pocket depth on probing, gingival recession (Ramfjord 1959), periodontal attachment loss (CAL=PPD+REC) and bleeding index (BOP) (Ainamo and Bay 1975).

The secondary objectives are:

1. To Investigate an association between the presence of periodontal disease and:

* the CFTR expression genotype (type of mutation)

* the ventilatory capacity (FEV1)

* the treatments administered and their mode of administration

* the value of glycated hemoglobin (Hba1c%)

2. To assess the prevalence of carious lesions in adult cystic fibrosis patients

3. To assess the impact of cystic fibrosis and its treatments on oral health-related quality of life.

4. To look for an association between periodontal clinical indices and the level of expression of genes encoding antimicrobial peptides

Study Timeline

• Study Start: 2023-07-20
• Status Verified: 2023-11
• Study First Submitted: 2023-11-10
• Study First Submitted QC: 2023-11-10
• Last Update Submitted: 2023-11-10
• Study First Posted: 2023-11-15
• Last Update Posted: 2023-11-15
• Primary Completion: 2025-01-20
• Study Completion: 2025-01-20

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
cystic fibrosis subjects	Periodontal examination	Adult patients with cystic fibrosis consulting the Resource and Competence Center for Cystic Fibrosis at the C.H.U. from Reims

Primary Outcome Measures

Name	Time	Method
Prevalence of periodontal disease	Day 0	Periodontal Disease will be diagnosed according to the new classification of periodontal diseases (Chicago, 2017) and defined by the decision-making algorithms (Tonetti and Sanz, 2019). Diagnosis will be based on Buccal or lingual Clinical attachment level (CAL), Recession (REC) and Periodontal Pocket Depths (PPD) measurement.

Secondary Outcome Measures

Name	Time	Method
Level of expression of antimicrobial peptides genes	Day 0	Evaluated by ΔΔCt compared to a classically used reference gene
Prevalence of carious lesions	Day 0	Evaluated by ICDAS (International Caries Detection and Assessment Score) (Ismaïl et al., 2007)
Oral Health Quality of Life	Day 0	GOHAI validated in French for general population -Tubert-Jeanin et al., 2003)

Trial Locations

Locations (1)

Damien JOLLY; 🇫🇷 Reims, France